, therapeutic strategies to maintain bone health, and treatment of bone metastases, including surgery for pathologic fractures. Multiple members of the health care team may be needed for effective patient care and education. This report summarizes presentations
Search Results
Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak
Heidi Ko, Yaser Baghdadi, Charito Love, and Joseph A. Sparano
advanced disease; it results in the downstaging of breast and regional nodal disease burden and facilitates breast conservation and/or less extensive axillary surgery. 2 Upstaging to a higher regional stage or detection of metastatic disease may impact
Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force
persists despite adjuvant therapy in many patients with breast cancer for up to 4 years after surgery. 14 Reports on the prognostic value of minimal residual disease detection show conflicting results. In a systematic review of published studies, minimal
Lina Jansen, Daniel Boakye, Elizabeth Alwers, Prudence R. Carr, Christoph Reissfelder, Martin Schneider, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner
characteristics (Charlson comorbidity score and regular use of statins and nonsteroidal anti‐inflammatory drugs [NSAIDs], including aspirin), tumor-related characteristics (year of diagnosis, cancer stage, and cancer site), and treatment characteristics (surgery
Héctor G. van den Boorn, Ameen Abu-Hanna, Nadia Haj Mohammad, Maarten C.C.M. Hulshof, Suzanne S. Gisbertz, Bastiaan R. Klarenbeek, Marije Slingerland, Laurens V. Beerepoot, Tom Rozema, Mirjam A.G. Sprangers, Rob H.A. Verhoeven, Martijn G.H. van Oijen, Koos H. Zwinderman, and Hanneke W.M. van Laarhoven
cancer can be treated with surgery with or without (neo)adjuvant chemo(radio)therapy. Potentially curable esophageal cancer can also be treated with definitive chemoradiotherapy. Metastatic disease is treated mainly with systemic therapy but also with
Hiram S. Cody III and Kimberly J. Van Zee
III trial 10853 . Lancet 2000 ; 355 : 528 – 533 . 21 Kestin LL Goldstein NS Martinez AA . Mammographically detected ductal carcinoma in situ treated with conservative surgery with or without radiation therapy: Patterns of failure and 10
Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris
distant metastatic site was seen. The patient received adjuvant concurrent chemotherapy and radiation with 6 cycles of weekly intravenous carboplatin (area under the curve, 2) and paclitaxel at 50 mg/m 2 . Four weeks after surgery she received 63 Gy of
Angela K. Green, Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, and Roisin E. O’Cearbhaill
therapy. A small proportion of patients with recurrent ovarian cancer may also be candidates for secondary cytoreductive surgery (SCS) for low-volume, isolated disease, which may be missed without routine surveillance imaging. Recent data suggest that
Elisabeth Kenne Sarenmalm, Salmir Nasic, Cecilia Håkanson, Joakim Öhlén, Eva Carlsson, Monica E. Pettersson, and Richard Sawatzky
-14). Sample and Setting The study sample was included in a large person-centered information and communication intervention among patients scheduled for elective CRC surgery. Patients were consecutively enrolled, and data were collected presurgery, including
Laura M. Spring, Yael Bar, and Steven J. Isakoff
Use of neoadjuvant therapy (NAT) for operable breast cancer has increased significantly over the past several years. Initially, interest in NAT centered around operability and improving eligibility for breast-conserving surgery. 1 Later, the
